Not Yet RecruitingNot Applicable

Subcutaneous Dexpanthenol Administration and Wound Epithelialization

Turkey (Türkiye)40 participantsStarted 2026-08-02

Plain-language summary

Chronic wounds are wounds that do not heal properly over time and can significantly reduce quality of life. Common types include diabetic foot ulcers, venous leg ulcers, and arterial ulcers. Improving wound healing and speeding up skin regeneration (epithelialization) are important goals in the care of these patients. Dexpanthenol is a vitamin B5 derivative that supports skin repair and tissue regeneration. It is widely used in topical treatments, and injectable forms are approved for clinical use. However, the effects of subcutaneous (under the skin) dexpanthenol injections on chronic wound healing have not been sufficiently studied in clinical settings. The purpose of this study is to evaluate whether adding subcutaneous dexpanthenol injections to standard wound care improves wound healing compared with standard wound care alone. Adult patients with non-infected chronic wounds will be randomly assigned to one of two groups. One group will receive standard wound care only, while the other group will receive standard wound care plus subcutaneous dexpanthenol injections around the wound area. Wound healing will be assessed by measuring changes in wound size and the degree of skin epithelialization over time using standardized and objective methods. Safety will be monitored by recording local reactions at the injection site and any other adverse events during the study. The results of this study may provide preliminary clinical evidence on the effectiveness and safety of subcutaneous dexpanthenol as an additional treatment option for chronic wound management.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged 18 years and older. * Presence of a chronic wound, including diabetic foot ulcer, venous leg ulcer, or arterial ulcer. * Target wound size between 1 and 20 cm² at baseline. * Non-infected wound, defined by the absence of purulent discharge, foul odor, spreading erythema, cellulitis, or systemic signs of infection. * Clinically stable patients without the need for systemic antibiotic therapy. * Ability to understand the study procedures and provide written informed consent. * Willingness and ability to comply with study visits and treatment schedule. Exclusion Criteria: * Clinical signs of wound infection or requirement for systemic antibiotic treatment. * Critical limb ischemia, defined as ankle-brachial index \<0.5, rest pain, gangrene, or extensive tissue necrosis. * Wounds exposing bone, tendon, or joint structures, or suspected osteomyelitis. * Wound size smaller than 1 cm² or larger than 20 cm². * Malignant, autoimmune, vasculitic, or specific dermatologic conditions causing the wound. * Known hypersensitivity or allergy to dexpanthenol or any component of the study treatments. * Pregnancy or breastfeeding. * Cognitive impairment or inability to provide informed consent. * Participation in another interventional clinical trial that could interfere with the outcomes of this study. * Any medical condition that, in the investigator's judgment, could compromise participant safety or study integrity.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Percentage Change in Wound Area

Timeframe: Baseline (Day 0) to Day 19 ±1 and Day 26 ±1

Trial details

NCT IDNCT07395674

SponsorDilara CANBAY OZDEMIR

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-08-02

View on ClinicalTrials.gov More Chronic Wounds trials